SLC5A2 and diabetes mellitus: To date there is not an established phenotype to help clinicians accurately predict the risk of DKA events when using an SGLT-2 inhibitor.14 However, the risk of DKA is higher in the following groups: older white males and those with a lower body mass index, higher HbA1c level, lower glomerular filtration rate, and longer duration of diabetes.